drugset / Trial / NCT01484977

eValuation of the Efficacy and toleRability of Vimpat When Added to lEvetiracetam

NCT01484977

Phase 3 Completed 120 enrolled UCB Pharma
NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the effectiveness of the study drug lacosamide (200-600 mg/day) when added to a stable dose of levetiracetam (1000-3000 mg/day) with withdrawal of the concomitant sodium channel blocking-antiepileptic drug (AEDs) in subjects not well controlled on their current regimen.

Timeline

Start
2011-12
Primary completion
2013-12
Completion
2013-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacosamide Other / unclassified 200 mg
Subject Lacosamide Other / unclassified 600 mg

Indications